In early April, a Federal Circuit panel found that a New Jersey federal judge ruled incorrectly that generics maker Teva had shown that a patent on a dosing regimen for a Johnson & Johnson’s schizophrenia drug was obvious based on a clinical trial protocol and other evidence.
This precedential opinion highlights the Federal Circuit’s views regarding key issues in generic drug cases. Law360 spoke with Finnegan partner Justin Hasford who said that the Federal Circuit's fact-intensive decision doesn't make new law, since the U.S. Supreme Court’s decision in KSR v. Teleflex held that "there shouldn't be sort of this rigid test for obviousness, and that's what the court applied here.”
Justin added that generics makers often argue that drug patents are obvious based on multiple references each covering one element of the patent, so he found it ironic that the generic side in the case was the one emphasizing creativity and what the evidence suggests when taken as a whole.
"That's not usually the way the generic side argues, but that was a successful argument here," Hasford said.
Read “3 Takeaways from Revived Obviousness Case On J&J Patent”
Press Release
May 17, 2024
Award/Ranking
Women in Business Law EMEA Awards 2024: Finnegan Nominated for German Firm of the Year
May 15, 2024
Award/Ranking
Finnegan Named Firm of the Year at the 2024 Managing Intellectual Property Americas Awards
April 26, 2024
Commentary
World IP Day: EPO Reveals 33% Jump in Cleantech Inventions Over Five Years
April 26, 2024
Award/Ranking
Finnegan Shortlisted for the 2024 Asian Legal Business Japan Law Awards
April 26, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.